Tirzepatide
A Study of LY3298176 (Tirzepatide) For the Maintenance of Body Weight Reduction in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly · Phase 3 · Completed · Enrollment 441
| Arm | Population | Dose | Weeks | Estimand | Weight change |
|---|---|---|---|---|---|
| Tirzepatide 5 milligram (mg) | Obesity or overweight | n/r | n/r | n/r | n/r |
| Tirzepatide Maximum Tolerated Dose | Obesity or overweight | n/r | n/r | n/r | n/r |
| Placebo | Obesity or overweight | n/r | n/r | n/r | n/r |